TRUSTED GLOBAL LEADER

Transcription

1 TRUSTED GLOBAL LEADER FULL YEAR RESULTS YEAR ENDED 30 JUNE 2017

2 OVERVIEW FY17 Highlights Gross profit* STRONG FULL YEAR PERFORMANCE FY M ALL OPERATIONS CONTRIBUTING TO GOOD LEVELS OF ORGANIC GROWTH FY M MORE THAN 20% GROWTH IN ADJUSTED GROSS PROFIT*, EBITDA* & EPS* FY M EBITDA (after SBP)* EPS (after SBP)* FY M FY p FY M FY p FY M FY p * Adjusted results exclude amortisation & non-underlying costs. Adjusted EBITDA includes the 50% share of the EBITDA from the joint venture in South Africa. Adjusted results are now shown after share-based payments & the prior year has been restated accordingly. Results are for the year ended 30 June Right Medicine Right Patient Right Time 2

3 THREE OPERATIONS IN FOCUS CLINICAL TRIAL SERVICES UNLICENSED MEDICINES COMMERCIAL MEDICINES Gross profit 23.3m +18% Gross profit 52.2m +19% Gross profit 47.3m +27% Clinigen CTS Idis MA, Idis GA and Link (unlicensed) Clinigen SP and Link (commercial) CHARACTERISTICS CHARACTERISTICS CHARACTERISTICS Global market leader Strong reputation Deep understanding of regulatory environment Global reach with local expertise Quality management system Global market leader International service & distribution network Expertise & local knowledge of regulatory frameworks Strong partnerships with pharma companies & pharmacists Range of hospital only niche products, including branded & generic Knowledge & expertise in licensed & unlicensed medicines Typically mature products * Graphs show % proportion of FY17 Group adjusted gross profit. % growth rates are FY17 versus FY16. The Unlicensed Medicines operation encompasses Managed Access, Global Access & the unlicensed business within Link Healthcare. The Commercial Medicines operation encompasses Specialty Pharmaceuticals & the commercial business within Link Healthcare. Right Medicine Right Patient Right Time 17 3

4 A DIVERSIFIED PORTFOLIO Gross profit by type 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% COMMERCIAL MEDICINES UNLICENSED MEDICINES CLINICAL TRIAL SERVICES SPECIALTY PHARMA LINK GLOBAL ACCESS MANAGED ACCESS CLINICAL TRIAL SERVICES HOSPITAL PHARMACISTS PHARMA COMPANIES ROW USA EUROPE OPERATION SUB DIVISION CUSTOMER GEOGRAPHY UK Indicative purposes only based on information for the year ended 30 June Copyright Clinigen Group plc. All rights reserved Right Right Medicine MedicineRight Right Patient Right Time 29 4

5 OUTSTANDING TRACK RECORD OF GROWTH The development of Clinigen Adjusted gross profit* Adjusted EBITDA* LINK M TOTECT FOSCAVIR BAG LINE EXTENSION 123M GROUP FORMED FOSCAVIR 7M 16M LIST ON AIM 29M CARDIOXANE 35M 17M 20M SAVENE & ETHYOL 41M 25M IDIS 54M 30M 101M 54M 65M 0 FY10 FY11 FY12 FY13 FY14 FY15 FY16 FY17 * Adjusted results exclude amortisation & non-underlying costs. Adjusted EBITDA includes the 50% share of the EBITDA from the joint venture in South Africa. Adjusted results are shown after share-based payments. CAGR growth covers the eight year period between FY10 and FY17. Right Medicine Right Patient Right Time 729 5

6 QUANTUM OVERVIEW Supplies unlicensed medicines & imported medicines licensed abroad Customers: healthcare professionals, hospital pharmacists, pharmacy groups Key competencies / competitive advantages: Service & quality Breadth of offering Contracted relationships Future strategy: UNLICENSED Identifying top selling unlicensed products Securing licences to protect market position LICENSED & UL2L PORTFOLIO In-house product development capability Portfolio & pipeline comprises: In-house development pipeline of UL2L products, being actively developed Larger niche generic pharmaceutical / hospital products for third party customers 35 products in various phases of development (over 70% are UL2L) Right Medicine Right Patient Right Time 19 6

7 STRATEGIC RATIONALE FOR ACQUISITION Highly complementary acquisition, strengthening Clinigen s position as global leader in ethical access to medicines Strategic rationale: Quantum s UL2L capabilities to accelerate Clinigen s UL2L global strategy Immediate global reach for Quantum s products & pipeline through Clinigen s infrastructure Continental European base site for potential expansion Capitalise on and grow Quantum s strong UL business Immediately earnings accretive Right Medicine Right Patient Right Time 19 7

8 POST ACQUISITION DIVISIONAL PROFILE Clinigen Operation CLINICAL TRIAL SERVICES UNLICENSED MEDICINES COMMERCIAL MEDICINES Definition Global leader Specialist supply & management Quality-assured comparator medicines & services Global leader Ethically sourcing & supplying unlicensed medicines Hospital pharmacists and physicians Acquisition & revitalisation Niche hospital-only products Critical care products Providing access Licensed and branded generic medicines Africa and AsiaPac regions Services IITs Comparator sourcing Added value services Early access Global access Specials UL2L Local licenses Acquisition / revitalisation Right Medicine Right Patient Right Time 19 8

9 IMMC ACQUISITION Japan s largest supplier of unlicensed medicines Gross profit of around 2.4m for year ended 30 September 2017 Operates throughout Japan in niche vaccine, oncology and IVF sectors Relationships with 850 hospitals and clinics Acquisition will contribute to strategy in becoming the go to global leader in ethical access to unlicensed medicines Acquisition immediately earnings enhancing Right Right Medicine Drug Right Patient Right Time 20 9 Copyright Clinigen Group plc. All rights reserved 3

10 STRATEGIC OBJECTIVES PEOPLE TECHNOLOGY CUSTOMER BUSINESS DEVELOP & RETAIN TALENTED PEOPLE UPGRADE TECHNOLOGY PLATFORM EXPAND AND EMBED A GLOBAL COMMUNITY OF CUSTOMERS & OPINION LEADERS EXPAND PORTFOLIO OF GLOBAL & REGIONAL ASSETS BECOME THE GO TO GLOBAL LEADER IN ACCESS TO UNLICENSED MEDICINES EXTEND GLOBAL FOOTPRINT INTO REMAINING KEY MARKETS TRUSTED GLOBAL LEADER Right Medicine Right Patient Right Time

11 SUMMARY Strong financial performance Significant progress made on strategic objectives Acquisition of Quantum adds to Clinigen s capability and accelerates global UL2L strategy IMMC presents long-term opportunity Well positioned to deliver another good year of progress Right Right Medicine Drug Right Patient Right Time Copyright Clinigen Group plc. All rights reserved 3